The rs6265 Polymorphism of the BDNF Gene in the Population of Patients with Multiple Sclerosis in the Tomsk Region

Objectives . To study the effects of the rs6265 polymorphism of the brain-derived neurotrophic factor ( BDNF ) gene on the risk of developing multiple sclerosis (MS), its main clinical characteristics, and the nature of responses to pathogenetic therapy. Materials and methods . The study group consi...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology 2023-11, Vol.53 (9), p.1497-1501
Main Authors: Titova, M. A., Alifirova, V. M., Kamenskikh, E. M., Musina, N. F., Nikolaeva, T. N., Paderina, D. Z., Boiko, A. S., Ivanova, S. A.
Format: Article
Language:English
Subjects:
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Brain-derived neurotrophic factor
Chloroform
DNA probes
Gene polymorphism
Genotyping
Methods of Investigation and Diagnostics
Multiple sclerosis
Neurobiology
Neurosciences
Nucleotide sequence
Polymerase chain reaction
Polymorphism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives . To study the effects of the rs6265 polymorphism of the brain-derived neurotrophic factor ( BDNF ) gene on the risk of developing multiple sclerosis (MS), its main clinical characteristics, and the nature of responses to pathogenetic therapy. Materials and methods . The study group consisted of 321 patients and the control group of 266 healthy people. DNA was extracted from venous blood using the standard phenol-chloroform method. Genotyping was carried out by real-time polymerase chain reaction (PCR) using competing TaqMan probes complementary to the polymorphic nucleotide sequence. Results . Carriage of the C allele and the CC genotype of the rs6265 polymorphism of the BDNF gene was found to be a factor determining a more favorable course of MS. Conclusions . Carriers of this genotype had a low rate of progression of MS, a lower frequency of exacerbations, and a less marked degree of disability, while disease duration was comparable; carriers also had a higher frequency of more optimal responses to therapy with first- and second-line MS disease-modifying drugs.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-023-01544-z